Evidence map›Paper›PMID 37753362›Full record

ArticleFuture science OA2023

A primary hepatic lymphoma in a patient with Crohn's disease receiving thiopurine and anti-TNF therapy: a case report.

Salma Merhaben, Shema Ayadi, Monia Tangour, Nadia Boujelbene, Rayfa Ghariani, Leila Mouelhi, Fathi Merhaben

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Salma MerhabenGastroenterology Department, Charles Nicolle hospital, Tunis, 1006, Tunisia.ORCID https://orcid.org/0009-0003-8380-3756
Shema AyadiGastroenterology Department, Charles Nicolle hospital, Tunis, 1006, Tunisia.
Monia TangourHistopathology Department, Salah Azaiez Institute, Tunis, 1007, Tunisia.
Nadia BoujelbeneHistopathology Department, Salah Azaiez Institute, Tunis, 1007, Tunisia.
Rayfa GharianiRadiology Department, El Amen private hospital, Nabeul, 8000, Tunisia.
Leila MouelhiGastroenterology Department, Charles Nicolle hospital, Tunis, 1006, Tunisia.
Fathi MerhabenGastroenterology Department, El Amen private hospital, Nabeul, 8000, Tunisia.
Hôpital Charles-Nicolle · TNInstitut Salah-Azaïz · TNAmen Clinics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary hepatic lymphoma is a rare variant of non-Hodgkin's lymphoma with an incidence of 0.016% of all non-Hodgkin lymphomas. The most common histologic subtype is large diffuse B-cell lymphoma. Pathogenesis is not clearly established and undergoing immunosuppressive therapy has been proposed as a risk factor for primary hepatic lymphoma. We report an intriguing case study, featuring a 23-year-old male patient with Crohn's Disease who had been receiving a combination therapy of thiopurine and anti-TNF for 6 years and was diagnosed with primary hepatic diffuse large B-cell lymphoma.

Indexed as

anti-TNF therapyCrohn's diseasediffuse large -B cell lymphomaprimary hepatic lymphomathiopurine

Identifiers

PMID37753362
PMCPMC10518835
OpenAlexW4386220278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.